Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 4/20 | 0.33 |
| ▸ | FFAR4 | Q5NUL3 | 4/20 | 0.33 |
| ▸ | HPGD | P15428 | 2/20 | 0.33 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | MET | P08581 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | GPR17 | Q13304 | 1/20 | 0.31 |
| ▸ | TSPO | P30536 | 1/20 | 0.30 |
| ▸ | DRD3 | P35462 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4155562 | 0.88 | MET (0.39) | FFAR1FFAR4HPGDSLC6A4CYP2C19 | |
| SCHEMBL3247524 | 0.86 | KDM4E (0.35) | HPGDMETKDM4EALDH1A1LMNA | |
| SCHEMBL3242027 | 0.81 | GABRA1 (0.36) | HPGDCYP2C19KDM4EALDH1A1LMNA | |
| Propionic Acid SCHEMBL4159519 | 0.79 | MET (0.34) | HPGDMETKDM4EALDH1A1LMNA | |
| SCHEMBL4160294 | 0.79 | FFAR1 (0.48) | FFAR1FFAR4HPGDCYP2C19GPR17 | |
| SCHEMBL4160259 | 0.79 | GABRA1 (0.41) | FFAR1FFAR4HPGDCYP2C19GPR17 | |
| SCHEMBL4162287 | 0.78 | HPGD (0.38) | FFAR1FFAR4HPGDCYP2C19GPR17 | |
| SCHEMBL4165404 | 0.77 | HPGD (0.42) | FFAR1FFAR4HPGDCYP2C19KDM4E | |
| SCHEMBL4155216 | 0.76 | GSK3B (0.40) | HPGDCYP2C19MAPTGPR17 | |
| SCHEMBL4162442 | 0.75 | HPGD (0.42) | HPGDCYP2C19KDM4EALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8426437-B2 | Pyrroloquinoline derivatives and their use as protein kinases inhibitors | PIERRE FABRE MEDICAMENT (FR) | 2013-04-23 | — | — | US | claimed |
| US-20090042876-A1 | Pyrroloquinoline Derivatives And Their Use As Protein Kinases Inhibitors | PIERRE FABRE MEDICAMENT (FR) | 2009-02-12 | — | — | US | claimed |
| US-8426437-B2 | Pyrroloquinoline derivatives and their use as protein kinases inhibitors | PIERRE FABRE MEDICAMENT (FR) | 2013-04-23 | — | — | US | disclosed |
| US-20090042876-A1 | Pyrroloquinoline Derivatives And Their Use As Protein Kinases Inhibitors | PIERRE FABRE MEDICAMENT (FR) | 2009-02-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090042876-A1 | Pyrroloquinoline Derivatives And Their Use As Protein Kinases Inhibitors | MAP3K1, MAP3K2, MAP3K7 | FFAR1 3984/4885FFAR4 4539/4885HPGD 882/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.